C
Crescent Biopharma, Inc. (CBIO)
NCM – Real vaqt narxi. Valyuta: USD
18.46
-0.06 (-0.32%)
Yopilishda: May 12, 2026, 4:00 PM EDT
18.20
-0.26 (-1.41%)
Bozordan keyin: May 12, 2026, 7:08 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
18.46
-0.06 (-0.32%)
Yopilishda: May 12, 2026, 4:00 PM EDT
18.20
-0.26 (-1.41%)
Bozordan keyin: May 12, 2026, 7:08 PM EDT
Crescent Biopharma, Inc., biotexnologiya kompaniyasi, Qo'shma Shtatlarda saraton terapiyasi nomzodlarini tadqiq qiladi va ishlab chiqadi. Uning portfelida CR-001 mavjud bo'lib, u 3-bosqich klinik sinovda, qattiq o'smalarni davolash uchun patentlangan anti-PD-1/anti-VEGF bispesifik antitel; va CR-002 hamda CR-003. Kompaniya onkologik terapevtik vositalarni ishlab chiqish va tijoratlashtirish bo'yicha Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. bilan strategik hamkorlikni yo'lga qo'ygan. Kompaniya ilgari GlycoMimetics, Inc. nomi bilan tanilgan. Kompaniya 2024-yilda tashkil etilgan va Uoltam, Massachusetsda joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Ellie Im M.D. | Chief Medical Officer |
| Dr. Jan Pinkas Ph.D. | Chief Scientific Officer |
| Dr. Jonathan McNeill M.D. | President & COO |
| Dr. Wenjie Cheng Ph.D. | Senior Vice President of Technical Operations |
| Mr. Christopher Doughty | Chief Business Officer |
| Mr. Joshua T. Brumm | CEO & Director |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-04-29 | 10-Q | cbio-20260331.htm |
| 2026-04-21 | DEFA14A | defa14-2026proxystatementx.htm |
| 2026-03-03 | POS AM | crescentbiopharma-posam.htm |
| 2026-02-26 | S-8 | crescent-formsx8xq12026xev.htm |
| 2026-01-13 | CORRESP | filename1.htm |
| 2026-01-07 | S-1 | cbio-20260107.htm |
| 2025-12-12 | S-4 POS | cbio-20251212.htm |
| 2025-12-04 | 8-K | cbio-20251202.htm |
| 2025-11-06 | 10-Q | cbio-20250930.htm |
| 2025-07-31 | 8-K | cbio-20250729.htm |
| Mr. Richard William Scalzo M.B.A. | Chief Financial Officer |
| Mr. Ryan Lynch | Senior VP of Finance, Treasurer & Chief Accounting Officer |
| Ms. Amy Reilly | Chief Communications Officer |
| Ms. Barbara Bispham Hale J.D. | General Counsel & Corporate Secretary |